Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics, Maintains $54 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $54 price target.
August 22, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $54.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Arcturus Therapeutics. The maintained price target of $54 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100